Measures Needed to Reduce Prevalence and Cost


Lead Author(s): 

William G. Ward, Sr., MD
David J. Sheedy, MPH
Elaine G. Russell, PhD, RN

Supporting Author(s): 

Sylvia I. Watkins-Castillo, PhD

The economic burden of SREs in patients with bone metastases is substantial. Several recent studies show that the estimated lifetime SRE-related cost per patient suffering from bone metastatic disease (BMD) resulted in medical costs more than twice the treatment cost for cancer in patients without BMD.1,2 Finding cures and effective treatments for all types of cancer can help reduce the prevalence and costs associated with bone and joint cancer.

Overall, cancers metastatic to bone cause significant pain and morbidity. Approximately 50% of patients with metastatic cancer of lung, breast, prostate, and kidney develop bony metastases prior to death. Untreated, these metastases can lead to pathological fractures and cause great pain and disability. Thus, the elucidation of the biochemical steps involved in bone destruction and the development of drugs to combat such steps, have been an example of tremendous scientific advancement and achievement in the field of cancer research and treatment.


  • 1. Decroisette C, Monnet I, Berard H, et al. Epidemiology and treatment costs of bone metastases from lung cancer: a French perspective, observational, multicenter study. Journal of Thoracic Oncology 2001;6(3):576-582.
  • 2. Hagiwara M, Oglesby A, Chung K, Zilber S. The impact of bone metastases and skeletal-related events on healthcare costs in prostate cancer patients receiving hormonal therapy. MDedge:Hematology & Oncology. Accessed August 14, 2019.


  • Fourth Edition

Chapter Graphs

To save an individual graph, right-click and select Save Image As

Topic Tables

Click on an image to view PDF